Stability of levodopa/carbidopa solutions.
作者信息
Cedarbaum J M
出版信息
Mov Disord. 1997 Jul;12(4):625.
PMID:9251095
Abstract
摘要
相似文献
1
Stability of levodopa/carbidopa solutions.
Mov Disord. 1997 Jul;12(4):625.
2
The stability of carbidopa in solution.
Mov Disord. 1997 Jul;12(4):608-10. doi: 10.1002/mds.870120422.
3
Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use.左旋多巴在溶液中的稳定性：时间进程、环境影响及临床使用的实用建议。
Mov Disord. 1996 Jan;11(1):24-6. doi: 10.1002/mds.870110106.
4
Report: Preparation of levodopa/carbidopa compound drug resins.
Pak J Pharm Sci. 2018 Jan;31(1):205-211.
5
Chaotropic agents in liquid chromatographic method development for the simultaneous analysis of levodopa, carbidopa, entacapone and their impurities.用于左旋多巴、卡比多巴、恩他卡朋及其杂质同时分析的液相色谱法开发中的离液试剂。
J Pharm Biomed Anal. 2013 Apr 15;77:9-15. doi: 10.1016/j.jpba.2013.01.007. Epub 2013 Jan 8.
6
Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.帕罗珂：一种卡比多巴/左旋多巴速溶制剂。
Med Lett Drugs Ther. 2005 Jan 31;47(1201):12.
7
Quality control of benserazide-levodopa and carbidopa-levodopa tablets by capillary zone electrophoresis.采用毛细管区带电泳法对苄丝肼-左旋多巴片和卡比多巴-左旋多巴片进行质量控制。
Electrophoresis. 2000 Jul;21(12):2432-7. doi: 10.1002/1522-2683(20000701)21:12<2432::AID-ELPS2432>3.0.CO;2-E.
8
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.盐酸多奈哌齐与左旋多巴/卡比多巴联合用于帕金森病患者：多次口服给药后药代动力学变化及安全性评估
Br J Clin Pharmacol. 2004 Nov;58 Suppl 1(Suppl 1):41-9. doi: 10.1111/j.1365-2125.2004.01799.x.
9
10
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.降低卡比多巴/左旋多巴的给药频率：双盲交叉研究，比较卡比多巴/左旋多巴每日两次双层制剂（IPX054）与稳定期帕金森病患者每日4次标准卡比多巴/左旋多巴的疗效。
Clin Neuropharmacol. 2009 Jul-Aug;32(4):189-92. doi: 10.1097/WNF.0b013e3181a27fae.
Zotero 插件